6 minute read
Nov. 14, 2023
Zunsemetinib: A p38α-MK2 Complex Inhibitor Intended for Inflammation
zunsemetinib
oral p38a-MK2 inhibitor Ph. IIa for hidradenitis suppurativa (failed) rational design from ATP-competitive molecule Press release, March 6, 2023 Confluence, MO / Aclaris Therapeutics, PA
Loading...
